Comparative Pharmacology
Head-to-head clinical analysis: ALDORIL D50 versus VALTURNA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDORIL D50 versus VALTURNA.
ALDORIL D50 vs VALTURNA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.
Valsartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the AT1 receptor, reducing vasoconstriction and aldosterone secretion. Aliskiren is a direct renin inhibitor that decreases renin activity, lowering angiotensin I and II levels.
1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.
One capsule orally once daily; dose depends on prior ARB or ACEi therapy: for patients not on an ARB or ACEi, start with 80/5 mg; for patients switching from an ARB, start with 160/5 mg; dose can be titrated to 160/5 mg or 320/10/12.5 mg based on BP response.
None Documented
None Documented
3–6 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for sustained blood pressure control; prolonged in renal impairment.
Aliskiren: terminal half-life ~24 hours (range 23-28 h), supports once-daily dosing; Valsartan: terminal half-life ~6 hours (range 5-9 h), but clinical effect persists >24 h due to sustained AT1 receptor blockade.
Renal: 50% as unchanged drug and 20% as metabolites; biliary/fecal: ~25% (as metabolites); total renal clearance accounts for ~70% of elimination.
Aliskiren: 78-90% of absorbed dose excreted unchanged via biliary/fecal route (hepatic), ~2.2% renal; Valsartan: 83% excreted unchanged in feces via bile, 13% renal.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination